4D Molecular Therapeutics, Inc. (FDMT) stock
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/302% above fair value
$12.12−0.88 (-6.74%)
Close on Nov 12, 2026Market cap $874.46MP/E –Yield –
4D Molecular Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
4D Molecular Therapeutics's total debt was $19.68M at Sep 30, 2026. For fiscal 2025 it was $0.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $19.68M | – |
| Q2 FY2026 | Jun 30, 2026 | $19.59M | – |
| Q4 FY2025 | Dec 31, 2025 | $0 | – |
See a number that looks wrong?